Radiofrequency Ablation for Primary Thyroid Cancer.
1/5 보강
Radiofrequency ablation (RFA) has emerged as a promising minimally invasive treatment for low-risk papillary thyroid carcinoma (PTC), particularly for low-risk papillary thyroid microcarcinomas.
APA
Hussain I (2026). Radiofrequency Ablation for Primary Thyroid Cancer.. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. https://doi.org/10.1016/j.eprac.2026.01.023
MLA
Hussain I. "Radiofrequency Ablation for Primary Thyroid Cancer.." Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2026.
PMID
41621643 ↗
Abstract 한글 요약
Radiofrequency ablation (RFA) has emerged as a promising minimally invasive treatment for low-risk papillary thyroid carcinoma (PTC), particularly for low-risk papillary thyroid microcarcinomas. This review summarizes the current evidence on the indications, efficacy, and safety of RFA in the management of PTC. Recent studies demonstrate a significant volume reduction with most tumors having a complete or near-complete response, low progression and recurrence rates and a favorable safety profile. RFA has the advantage of preserving thyroid function, avoiding visible scarring, and reduced recovery time. Emerging guidelines and international consensus statements now acknowledge RFA as a viable option in carefully selected cases, particularly for tumors less than 1 cm in maximum diameter without extrathyroidal extension or nodal involvement. Existing data support RFA as an effective, safe, and well-tolerated alternative to surgery and active surveillance for managing low-risk PTC, though more long-term data are needed to confirm durability. Since outcomes are operator-dependent, the growing demand for this procedure necessitates the development of centers of excellence with experienced operators.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Mechanism of cancer-associated fibroblast-driven thyroid cancer dedifferentiation via the ZFP57-PKM2 axis-mediated lactate secretion and therapeutic intervention with resveratrol.
- CHI3L1 Is Associated With TP53 Signaling and Promotes Papillary Thyroid Carcinoma Progression.
- The Role of Mean Platelet Volume (MPV) in Thyroid Cancers: A Scoping Review.
- Bilaterality in papillary thyroid carcinoma: long-term outcomes and predictive factors.
- Differentiated and Poorly Differentiated Thyroid Carcinoma in Ovarian Teratoma With Primary Papillary Thyroid Carcinoma: A Series of Two Case Reports.
- Radioiodine ablation in a haemodialysis-dependent patient with papillary thyroid carcinoma.